Vertex has reported a phase 2 win that still dented confidence in its pain prospect suzetrigine. The trial linked the ...

A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.

A single-center retrospective study in China found a significant association between pain duration and intensity in patients ...

Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their ...